| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$451.7M | ROE | −55.71% |
| Net Margin | — | ROIC | — |
| Debt / Equity | 0.15 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Dyne Therapeutics is a clinical-stage company developing therapeutics for neuromuscular diseases in the United States. Its pipeline targets myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease, as well as rare skeletal, cardiac, and metabolic muscle disorders, using its FORCE platform to deliver disease-modifying treatments.
| Market Cap | $3.70B | Trading Days | 2855 |
| 52W High | 26.26 |
| 52W Low | 8.88 |
| % Off High | −1.37% |
| YTD | 32.41% | 1Y | 178.20% |
| 3Y | 120.05% | 5Y | 32.35% |
| 10Y | 62.18% | Since incept. (ann.) | 2.15% |
| Ann. Volatility (1Y) | 78.48% | Ann. Volatility (3Y) | 84.33% |
| Sharpe (1Y) | 1.69 | Sharpe (3Y) | 0.77 |
| Max Drawdown (1Y) | −39.89% | Max Drawdown (3Y) | −85.52% |
| Beta (3Y, vs SPY) | 2.30 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | $3.55B | — |
| CPRX | CATALYST PHARMACEUTICALS, INC. | $3.85B | 18.7 |
| OGN | Organon & Co. | $3.55B | 18.8 |
| TNGX | Tango Therapeutics, Inc. | $3.85B | — |
| VKTX | Viking Therapeutics, Inc. | $3.93B | — |
| RCUS | Arcus Biosciences, Inc. | $3.40B | — |
| ELVN | Enliven Therapeutics, Inc. | $3.27B | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.18B | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.34B | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $4.45B | 11.3 |
| MANE | Veradermics, Inc | $4.66B |
| CUE | Cue Biopharma, Inc. | $2.87B | — |
